Clinical trials: Second-Line
HIV
Etiology of Treatment Failure in HIV Positive Children and Adolescents on Boosted Protease Inhibitor-based Regimens
Highly active antiretroviral therapy (HAART) transformed a once fatal condition into a chronic, manageable condition. However, it is estimated that 20-40% of patients on 2nd line treatment (2 nucleotide reverse transcriptase…
- Trial name
- ATF (NCT02689895)
- Testing
- modified directly administered anti-retroviral therapy (mDAART)
- Where
- 2 sites in Zimbabwe
- Volunteers
- 50 people
- Sponsor
- University of Zimbabwe
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma
Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of selinexor and docetaxel and to see how well they work when given together in treating patients with squamous cell lung cancer that has come back or spread to other…
- Trial name
- NCT02536495
- Testing
- Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study
- Sponsor
- Erin Bertino
Carcinoma, Non-Small-Cell Lung
Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC
The trial objective will be to evaluate whether BI 6727 monotherapy or in combination with pemetrexed may be effective in the treatment of advanced or metastatic NSCLC in patients who relapsed after or failed first-line platinum…
- Trial name
- NCT00824408
- Testing
- pemetrexed, BI 6727
- Where
- 12 sites in Canada, The Bahamas
- Volunteers
- 143 people
- Sponsor
- Boehringer Ingelheim
Advanced or Metastatic Breast Cancer
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer.
- Trial name
- NCT06105632
- Testing
- PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus
- Where
- 48 sites in United States, Argentina and 12 more
- Volunteers
- 333 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5
This is a phase II open label, single arm study evaluating treatment with pazopanib post sunitinib treatment in 43 patients with metastatic renal cell carcinoma.
- Trial name
- NCT01566747
- Testing
- Pazopanib
- Where
- 9 sites in Ireland, Sweden
- Volunteers
- 43 people
- Sponsor
- Cancer Trials Ireland
Rheumatoid Arthritis
Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice
To compare retention rates of adalimumab, etanercept and infliximab as first-line biotherapy in rheumatoid arthritis (RA), to determine causes of discontinuation, retention-associated factors, and retention rates of possible…
- Trial name
- MAINTAIN (NCT01692899)
- Volunteers
- 780 people
- Sponsor
- Pfizer
Advanced Hepatocellular Carcinoma
Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study
Evaluation of the efficacy and safety of adding rituximab after failure of target immunotherapy in the Posterior treatment of advanced hepatocellular carcinoma
- Trial name
- NCT06301399
- Testing
- Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Gastric Cancer
TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer
This is an open-label, single arm study evaluating the safety and tolerability of TEW-7197 in combination with paclitaxel in metastatic gastric cancer patients.
- Trial name
- NCT03698825
- Testing
- TEW-7197
- Where
- 6 sites in South Korea
- Volunteers
- 62 people
- Sponsor
- MedPacto, Inc.
Recurrent Liver Cancer After Liver Transplantation
Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation
For patients with recurrent liver cancer after liver transplantation, the median survival time is low and the prognosis is often poor.
- Trial name
- NCT05833126
- Testing
- Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shuhong Yi
Metastatic Breast Cancer
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
The primary objective for the Phase I portion of the study is to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) and for the Phase II portion of the study is to evaluate progression free survival…
- Trial name
- NCT00924352
- Testing
- Dasatinib, Ixabepilone
- Where
- 13 sites in United States
- Volunteers
- 56 people
- Sponsor
- Accelerated Community Oncology Research Network
Advanced Non Small Cell Lung Cancer, Uterine Cancer
Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer
In this one-arm study, histologically or cytologically confirmed advanced NSCLC, uterine malignancies, and soft tissue sarcoma will be enrolled to investigate the efficacy and safety of PD-1 monoclonal antibody SHR-1210 and…
- Conditions
- Advanced Non Small Cell Lung Cancer, Uterine Cancer, Soft Tissue Sarcoma
- Trial name
- NCT04239443
- Testing
- PD-1 inhibitor, Apatinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Hunan Cancer Hospital
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and carboplatin in patients receiving first- or…
- Trial name
- PRESERVE 2 (NCT04799249)
- Testing
- Trilaciclib, Gemcitabine, Carboplatin
- Where
- 71 sites in United States, Australia and 9 more
- Volunteers
- 194 people
- Sponsor
- G1 Therapeutics, Inc.
Advanced Colorectal Cancer, Colorectal Cancer
A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
Patients with histologically or cytologically confirmed metastatic colorectal cancer (CRC) who have failed a first-line chemotherapeutic regimen containing oxaliplatin and 5-fluorouracil (5-FU) with or without bevacizumab, with…
- Trial name
- NCT00498407
- Testing
- CP-4055
- Where
- 4 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- Clavis Pharma
Previously AG Chemotherapy Treated Pancreatic Cancer
Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer
This is a prospective, single arm, phase II clinical study investigating second-line Zimberelimab and SIROX chemotherapy for patient with previously AG chemotherapy treated pancreatic cancer.
- Trial name
- NCT06166589
- Testing
- Zimberelimab, Oxaliplatin, S-1
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Shanghai Zhongshan Hospital
HER2-negative Breast Cancer
Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer
This study intends to conduct a single-arm, open-label Phase II multicenter clinical study of gemcitabine combined with eribulin regimen in the treatment of second-line above recurrent HER2-negative breast cancer.
- Trial name
- NCT05263882
- Testing
- Gemcitabine combined with eribulin
- Volunteers
- 58 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Recurrent or Metastatic Cervical Cancer
Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer
This phase II study will evaluate the efficacy and safety of relacorilant in combination with nab-paclitaxel in participants with recurrent or metastatic cervical cancer who have previously received platinum-based chemotherapy…
- Trial name
- STELLA (NCT07763496)
- Testing
- Relacorilant, Nab-paclitaxel
- Where
- 2 sites in France
- Volunteers
- 63 people
- Sponsor
- ARCAGY/ GINECO GROUP
Squamous Non-small Cell Lung Cancer
Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)
The study's hypothesis is that using Nivolumab as early switch maintenance, after 4-6 cycles of standard first-line chemotherapy, might improve survival in patients with advanced stage squamous NSCLC.
- Trial name
- EDEN (NCT03542461)
- Testing
- Nivolumab 10 MG/ML Intravenous Solution, Best Supportive Care
- Where
- 31 sites in Italy
- Volunteers
- 125 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Treatment Failure of Second-line ART in Asian HIV-infected Children
Second-line Therapy
This study will help identify which ARV candidates should be prioritized for pediatric use in resource-limited settings
- Trial name
- TASER-P (NCT01788891)
- Where
- 8 sites in Indonesia, Malaysia and 2 more
- Volunteers
- 300 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Gastric Adenocarcinoma
Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma
In previous studies,the investigators found that POF (A combination of oxaliplatin, fluorouracil and Paclitaxel) regimen appears to be of good efficacy and is well tolerated in patients with advanced gastric cancer.
- Trial name
- NCT03788174
- Testing
- Apatinib, POF
- Where
- 2 sites in China
- Volunteers
- 26 people
- Sponsor
- Fujian Cancer Hospital
Chronic Graft-Versus-Host Disease
A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease
There is a clear need for effective, steroid-sparing agents for the management of chronic graft-versus-host disease (GVHD). Thus, agents like Histone deacetylase (HDAC) inhibitors, with the potential of decreasing…
- Trial name
- NCT01028313
- Testing
- LBH589, Methylprednisolone
- Where
- United States
- Sponsor
- SCRI Development Innovations, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.